CD274 and head and neck squamous cell carcinoma: The phase III trial Checkmate 141, which included 361 patients with R/M HNSCC who progressed after platinum-based regimens were randomized to receive nivolumab or mono-chemotherapy based on the investigator’s choice, led to the approval of nivolumab in this disease setting regardless of the PD-L1 expression [6].